CareDx Inc (CDNA)vsMerck & Company Inc (MRK)
CDNA
CareDx Inc
$28.82
-3.76%
HEALTHCARE · Cap: $1.20B
MRK
Merck & Company Inc
$128.66
+2.56%
HEALTHCARE · Cap: $283.78B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 15831% more annual revenue ($65.77B vs $412.82M). MRK leads profitability with a 13.6% profit margin vs -2.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).
CDNA
Hold37
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+57.7%
Fair Value
$46.59
Current Price
$28.82
$17.77 discount
Margin of Safety
-40.6%
Fair Value
$80.96
Current Price
$128.66
$47.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 39.0% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 1.5%
Weak financial health signals
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CDNA
The strongest argument for CDNA centers on Revenue Growth, Debt/Equity. Revenue growth of 39.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : CDNA
The primary concerns for CDNA are EPS Growth, Market Cap, Operating Margin.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
CDNA profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
CDNA carries more volatility with a beta of 2.48 — expect wider price swings.
CDNA is growing revenue faster at 39.0% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 37/100). CDNA offers better value entry with a 57.7% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CareDx Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?